Hence, we can speculate that the downregulation of CD44 expression upon pan-HDACi treatment has the potential to sensitize to therapy myeloma CSC in the bone marrow niche, a hypothesis that needs further evaluation. Here, CD44 is linked to plasma cell myeloma.